Gastroenterology
Volume 139, Issue 1 , Pages 58-72.e4 , July 2010

Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis

  • Albert J. Czaja

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • Corresponding Author InformationReprint requests Address requests for reprints to: Albert J. Czaja, MD, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905. fax: (507) 284-0538
  • ,
  • Michael P. Manns

      Affiliations

    • Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Hannover, Germany

Received 27 March 2010 ,Accepted 30 April 2010.

  • Image Result

    Flow chart of therapy for AIH. Patients are given only corticosteroids or a lower dose of corticosteroids in combination with azathioprine (preferred initial regimen). The outcomes of initial therapy

    Flow chart of therapy for AIH. Patients are given only corticosteroids or a lower dose of corticosteroids in combination with azathioprine (preferred initial regimen). The outcomes of initial therapy dictate changes in the treatment strategy.

  • Image Result
    Putative pathogenic pathways of AIH. The antigenic peptide (a self-antigen or foreign antigen that resembles a self-antigen) is displayed in the antigen-binding groove of a class II molecule of the MH

    Putative pathogenic pathways of AIH. The antigenic peptide (a self-antigen or foreign antigen that resembles a self-antigen) is displayed in the antigen-binding groove of a class II molecule of the MHC. Genetic factors, especially DRB1*0301 and DRB1*0401 in white North American and northern European adults, encode the structure of the antigen-binding groove and affect the nature of the antigen that can be accommodated. Recognition of the antigen display on the surface of the antigen-presenting cell (APC) by the CD4+ T-cell completes the first costimulatory signal necessary for immunocyte activation (1st signal). Ligation of a B7 molecule on the surface of the APC with the CD28 molecule on the surface of the CD4+ T cell completes the second costimulatory signal necessary for immunocyte activation (2nd signal). The activated CD4+ T cells produce signature cytokines that facilitate the clonal expansion of liver-infiltrating cytotoxic T cells (type 1 cytokine response) or plasma cells that produce Ig (type 2 cytokine response). Deficiencies in the number and function of the Treg cells and NK cells and genetic polymorphisms in TNFA*2 and TNFRSF6 increase the type 1 cytokine response and proliferation of liver-infiltrating cytotoxic T cells. Hepatocyte apoptosis is accomplished by binding of the Fas ligand of the cytotoxic T cell to the Fas molecule on the hepatocyte surface (cell-mediated cytotoxicity). The Igs produced by the expanded clone of plasma cells, possibly as a consequence of deficient Treg and NKT cell function, bind to normal constituents of the hepatocyte membrane and attract NK cells with Fc receptors. The hepatocytes undergo cytolysis (antibody-mediated cellular cytotoxicity). IgG4 staining can be used to characterize some of the plasma cells.

 Conflicts of interest The authors disclose no conflicts.

PII: S0016-5085(10)00661-X

doi: 10.1053/j.gastro.2010.04.053

Gastroenterology
Volume 139, Issue 1 , Pages 58-72.e4 , July 2010